Literature DB >> 12400611

A complex karyotype involving chromosomes 3, 6, 11, 12, and 22 in adult acute lymphoblastic leukemia.

Subramaniyam Shivakumar1, Susan Mathew, James Dalton, Mammen Chandy, Alok Srivastava.   

Abstract

Complex chromosomal abnormalities are rare in adult patients with acute lymphoblastic leukemia (ALL). Using molecular methods, we characterized a complex karyotype involving chromosomes 3, 6, 11, 12, and 22 in a 38-year-old man with ALL. Cytogenetic analysis revealed the following karyotype: 46,XY,der(3)t(3;?6)(q22;?p21), - 6,add(11)(q23),add(12)(p13), + mar[10]/46,XY[19]. Because patients with 11q23 abnormalities have a poor prognosis and require aggressive treatment, we used fluorescence in situ hybridization (FISH) to fully characterize the abnormalities. FISH analysis showed no rearrangement of the MLL or ETV6-CBFA2 (TEL-AML1) genes; the wild-type ETV6 allele was deleted in most cells. The revised karyotype after the FISH analysis was as follows: 46,XY,der(3)t(3;12)(p13;p?13)del(3)(q21),der(6)inv(6)(p21q21)ins(6;3)(q21;q21q25),der(11)t (3; 11)(q25;q23),der(12)t(11; 12)(q23;p?12),t(12;22)(p13;q13). Although structural abnormalities involving 11q23 and 12p13 bands were identified by conventional cytogenetics, this report clearly demonstrates that molecular assays are needed to fully characterize gene rearrangements, complex translocations as well as to assign patients to the appropriate treatment group.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12400611     DOI: 10.1080/1042819021000003018

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  1 in total

1.  Establishment of a novel human lymphoblastic cell strain with the long arm of chromosome 11 aberration without MLL rearrangement.

Authors:  Qian Wang; Lin Zhuang; Pei Li; Qiang Niu; Ping Zhu; Miao-Xia He; Hui Jiang; Chang-Cheng Liu; Min-Jun Wang; Li Chen; Hui Cheng; Yan Ma; Xiao-Xia Hu; Yi-Ping Hu; Xiao-Ping Xu
Journal:  Sci Rep       Date:  2017-04-13       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.